Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPPH Photodynamic Therapy for Barrett's Esophagus and Early Esophageal Cancer
NCT00281736Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Feb 2004
- Primary completion
- Jul 2007
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hpph in Barrett's esophagus and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Efficacy at 3 years. Started Feb 2004; status: completed.
02
Drugs
hpph
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00281736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281736.